Explore
Validate
Learn
Flow cytometryAntibody data
- Antibody Data
- Antigen structure
- References [60]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN1383944 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-IL-6 antibody
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Ion exchange chromatography
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- B-E8
- Vial size
- 500μl
- Concentration
- 500μg/500μl
- Storage
- Declared stable after 7 days at room temperature. Protect from light. Do not freeze.
Submitted references Unraveling viral interleukin-6 binding to gp130 and activation of STAT-signaling pathways independently of the interleukin-6 receptor.
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.
Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma.
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.
Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol.
Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia.
An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis.
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.
Interleukin 6 receptor as a target for the treatment of rheumatoid arthritis.
Human cardiomyocyte hypertrophy induced in vitro by gp130 stimulation.
Interferon-gamma switches monocyte differentiation from dendritic cells to macrophages.
Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints.
Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.
Coming of age: anti-cytokine therapies.
Interleukin-6 is a growth factor for nonmalignant human plasmablasts.
Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial.
Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders.
Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy.
STAT3 is constitutively activated in Hodgkin cell lines.
IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells.
Increased levels of interleukin-6 are associated with lymphocytosis in bronchoalveolar lavage fluids of idiopathic nonspecific interstitial pneumonia.
A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma.
Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors.
Human anti-animal antibody interferences in immunological assays.
Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells.
Human interleukin-6 is in vivo an autocrine growth factor for human herpesvirus-8-infected malignant B lymphocytes.
Down-regulation of CD1 on antigen-presenting cells by infection with Mycobacterium tuberculosis.
Preincubation of human resting T cell clones with interleukin 10 strongly enhances their ability to produce cytokines after stimulation.
Monoclonal antibody therapy in rheumatoid arthritis.
The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells.
Dimerization and activation of the common transducing chain (gp130) of the cytokines of the IL-6 family by mAb.
Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor.
Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma.
IL-6 and soluble IL-6 receptors (sIL-6R and sgp130) in human pleural effusions: massive IL-6 production independently of underlying diseases.
Analysis of the human interleukin-6/human interleukin-6 receptor binding interface at the amino acid level: proposed mechanism of interaction.
Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop.
In vivo role of IL-6 on the viral load and on immunological abnormalities of HIV-infected patients.
Combination therapy of anti-CD4 and anti-IL6 monoclonal antibodies in a case of severe spondylarthropathy.
Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments.
Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells.
Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus.
Clinical and immunological follow-up of patients with AIDS-associated Kaposi's sarcoma treated with an anti-IL-6 monoclonal antibody.
Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma.
Therapeutic monoclonal antibodies.
Different combinations of retinoids and vitamin D3 analogs efficiently promote growth inhibition and differentiation of myelomonocytic leukemia cell lines.
Pharmacokinetics of interleukin-6 during therapy with anti-interleukin-6 monoclonal antibodies: enhanced clearance of interleukin-6 by a combination of three anti-interleukin-6 antibodies.
Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms.
Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6.
Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody.
Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma.
Role of IL-6 in promoting growth of human EBV-induced B-cell tumors in severe combined immunodeficient mice.
Effects of an anti-interleukin-6 (IL-6) murine monoclonal antibody in a patient with acute monoblastic leukemia.
Role of interleukin-6 in paraneoplastic thrombocytosis.
Overall interleukin-6 production exceeds 7 mg/day in multiple myeloma complicated by sepsis.
High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo.
Interleukin-6 dependence of advanced malignant plasma cell dyscrasias.
Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia.
IL-6 and IL-6 receptor modulation by IFN-gamma and tumor necrosis factor-alpha in human monocytic cell line (THP-1). Priming effect of IFN-gamma.
Human recombinant dimeric IL-6 binds to its receptor as detected by anti-IL-6 monoclonal antibodies.
IFN-alpha induces autocrine production of IL-6 in myeloma cell lines.
Adam N, Rabe B, Suthaus J, Grötzinger J, Rose-John S, Scheller J
Journal of virology 2009 May;83(10):5117-26
Journal of virology 2009 May;83(10):5117-26
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.
Sprynski AC, Hose D, Caillot L, Réme T, Shaughnessy JD Jr, Barlogie B, Seckinger A, Moreaux J, Hundemer M, Jourdan M, Meissner T, Jauch A, Mahtouk K, Kassambara A, Bertsch U, Rossi JF, Goldschmidt H, Klein B
Blood 2009 May 7;113(19):4614-26
Blood 2009 May 7;113(19):4614-26
Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma.
Moreau P, Garban F, Attal M, Michallet M, Marit G, Hulin C, Benboubker L, Doyen C, Mohty M, Yakoub-Agha I, Leyvraz S, Casassus P, Avet-Loiseau H, Garderet L, Mathiot C, Harousseau JL, IFM Group
Blood 2008 Nov 1;112(9):3914-5
Blood 2008 Nov 1;112(9):3914-5
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.
Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, Lamy T, Marit G, Maloisel F, Berthou C, Dib M, Caillot D, Deprijck B, Ketterer N, Harousseau JL, Sotto JJ, Moreau P
Blood 2006 May 1;107(9):3474-80
Blood 2006 May 1;107(9):3474-80
Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol.
Moreau P, Hullin C, Garban F, Yakoub-Agha I, Benboubker L, Attal M, Marit G, Fuzibet JG, Doyen C, Voillat L, Berthou C, Ketterer N, Casassus P, Monconduit M, Michallet M, Najman A, Sotto JJ, Bataille R, Harousseau JL, Intergroupe Francophone du Myélome group
Blood 2006 Jan 1;107(1):397-403
Blood 2006 Jan 1;107(1):397-403
Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia.
Derhaschnig U, Bergmair D, Marsik C, Schlifke I, Wijdenes J, Jilma B
Critical care medicine 2004 May;32(5):1136-40
Critical care medicine 2004 May;32(5):1136-40
An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis.
Mahtouk K, Jourdan M, De Vos J, Hertogh C, Fiol G, Jourdan E, Rossi JF, Klein B
Blood 2004 Mar 1;103(5):1829-37
Blood 2004 Mar 1;103(5):1829-37
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.
Moreaux J, Legouffe E, Jourdan E, Quittet P, Rème T, Lugagne C, Moine P, Rossi JF, Klein B, Tarte K
Blood 2004 Apr 15;103(8):3148-57
Blood 2004 Apr 15;103(8):3148-57
Interleukin 6 receptor as a target for the treatment of rheumatoid arthritis.
Choy E
Annals of the rheumatic diseases 2003 Nov;62 Suppl 2:ii68-9
Annals of the rheumatic diseases 2003 Nov;62 Suppl 2:ii68-9
Human cardiomyocyte hypertrophy induced in vitro by gp130 stimulation.
Ancey C, Menet E, Corbi P, Fredj S, Garcia M, Rücker-Martin C, Bescond J, Morel F, Wijdenes J, Lecron JC, Potreau D
Cardiovascular research 2003 Jul 1;59(1):78-85
Cardiovascular research 2003 Jul 1;59(1):78-85
Interferon-gamma switches monocyte differentiation from dendritic cells to macrophages.
Delneste Y, Charbonnier P, Herbault N, Magistrelli G, Caron G, Bonnefoy JY, Jeannin P
Blood 2003 Jan 1;101(1):143-50
Blood 2003 Jan 1;101(1):143-50
Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints.
Smith MD, Barg E, Weedon H, Papengelis V, Smeets T, Tak PP, Kraan M, Coleman M, Ahern MJ
Annals of the rheumatic diseases 2003 Apr;62(4):303-7
Annals of the rheumatic diseases 2003 Apr;62(4):303-7
Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.
Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, Bataille R, Amiot M
Blood 2002 Jul 1;100(1):194-9
Blood 2002 Jul 1;100(1):194-9
Coming of age: anti-cytokine therapies.
Song XY, Torphy TJ, Griswold DE, Shealy D
Molecular interventions 2002 Feb;2(1):36-46
Molecular interventions 2002 Feb;2(1):36-46
Interleukin-6 is a growth factor for nonmalignant human plasmablasts.
Jego G, Bataille R, Pellat-Deceunynck C
Blood 2001 Mar 15;97(6):1817-22
Blood 2001 Mar 15;97(6):1817-22
Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial.
Haddad E, Paczesny S, Leblond V, Seigneurin JM, Stern M, Achkar A, Bauwens M, Delwail V, Debray D, Duvoux C, Hubert P, Hurault de Ligny B, Wijdenes J, Durandy A, Fischer A
Blood 2001 Mar 15;97(6):1590-7
Blood 2001 Mar 15;97(6):1590-7
Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders.
Leblond V, Dhedin N, Mamzer Bruneel MF, Choquet S, Hermine O, Porcher R, Nguyen Quoc S, Davi F, Charlotte F, Dorent R, Barrou B, Vernant JP, Raphael M, Levy V
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001 Feb 1;19(3):772-8
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001 Feb 1;19(3):772-8
Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy.
Corbellino M, Bestetti G, Scalamogna C, Calattini S, Galazzi M, Meroni L, Manganaro D, Fasan M, Moroni M, Galli M, Parravicini C
Blood 2001 Dec 1;98(12):3473-5
Blood 2001 Dec 1;98(12):3473-5
STAT3 is constitutively activated in Hodgkin cell lines.
Kube D, Holtick U, Vockerodt M, Ahmadi T, Haier B, Behrmann I, Heinrich PC, Diehl V, Tesch H
Blood 2001 Aug 1;98(3):762-70
Blood 2001 Aug 1;98(3):762-70
IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells.
Menetrier-Caux C, Thomachot MC, Alberti L, Montmain G, Blay JY
Cancer research 2001 Apr 1;61(7):3096-104
Cancer research 2001 Apr 1;61(7):3096-104
Increased levels of interleukin-6 are associated with lymphocytosis in bronchoalveolar lavage fluids of idiopathic nonspecific interstitial pneumonia.
Park CS, Chung SW, Ki SY, Lim GI, Uh ST, Kim YH, Choi DI, Park JS, Lee DW, Kitaichi M
American journal of respiratory and critical care medicine 2000 Sep;162(3 Pt 1):1162-8
American journal of respiratory and critical care medicine 2000 Sep;162(3 Pt 1):1162-8
A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma.
Moreau P, Harousseau JL, Wijdenes J, Morineau N, Milpied N, Bataille R
British journal of haematology 2000 Jun;109(3):661-4
British journal of haematology 2000 Jun;109(3):661-4
Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors.
Gu ZJ, De Vos J, Rebouissou C, Jourdan M, Zhang XG, Rossi JF, Wijdenes J, Klein B
Leukemia 2000 Jan;14(1):188-97
Leukemia 2000 Jan;14(1):188-97
Human anti-animal antibody interferences in immunological assays.
Kricka LJ
Clinical chemistry 1999 Jul;45(7):942-56
Clinical chemistry 1999 Jul;45(7):942-56
Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells.
Jego G, Robillard N, Puthier D, Amiot M, Accard F, Pineau D, Harousseau JL, Bataille R, Pellat-Deceunynck C
Blood 1999 Jul 15;94(2):701-12
Blood 1999 Jul 15;94(2):701-12
Human interleukin-6 is in vivo an autocrine growth factor for human herpesvirus-8-infected malignant B lymphocytes.
Foussat A, Wijdenes J, Bouchet L, Gaidano G, Neipel F, Balabanian K, Galanaud P, Couderc J, Emilie D
European cytokine network 1999 Dec;10(4):501-8
European cytokine network 1999 Dec;10(4):501-8
Down-regulation of CD1 on antigen-presenting cells by infection with Mycobacterium tuberculosis.
Stenger S, Niazi KR, Modlin RL
Journal of immunology (Baltimore, Md. : 1950) 1998 Oct 1;161(7):3582-8
Journal of immunology (Baltimore, Md. : 1950) 1998 Oct 1;161(7):3582-8
Preincubation of human resting T cell clones with interleukin 10 strongly enhances their ability to produce cytokines after stimulation.
Lelievre E, Sarrouilhe D, Morel F, Preud'Homme JL, Wijdenes J, Lecron JC
Cytokine 1998 Nov;10(11):831-40
Cytokine 1998 Nov;10(11):831-40
Monoclonal antibody therapy in rheumatoid arthritis.
Choy EH, Kingsley GH, Panayi GS
British journal of rheumatology 1998 May;37(5):484-90
British journal of rheumatology 1998 May;37(5):484-90
The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells.
Jourdan M, Ferlin M, Legouffe E, Horvathova M, Liautard J, Rossi JF, Wijdenes J, Brochier J, Klein B
British journal of haematology 1998 Mar;100(4):637-46
British journal of haematology 1998 Mar;100(4):637-46
Dimerization and activation of the common transducing chain (gp130) of the cytokines of the IL-6 family by mAb.
Autissier P, De Vos J, Liautard J, Tupitsyn N, Jacquet C, Chavdia N, Klein B, Brochier J, Gaillard JP
International immunology 1998 Dec;10(12):1881-9
International immunology 1998 Dec;10(12):1881-9
Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor.
Menetrier-Caux C, Montmain G, Dieu MC, Bain C, Favrot MC, Caux C, Blay JY
Blood 1998 Dec 15;92(12):4778-91
Blood 1998 Dec 15;92(12):4778-91
Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma.
Blay JY, Rossi JF, Wijdenes J, Menetrier-Caux C, Schemann S, Négrier S, Philip T, Favrot M
International journal of cancer. Journal international du cancer 1997 Jul 29;72(3):424-30
International journal of cancer. Journal international du cancer 1997 Jul 29;72(3):424-30
IL-6 and soluble IL-6 receptors (sIL-6R and sgp130) in human pleural effusions: massive IL-6 production independently of underlying diseases.
Doré P, Lelièvre E, Morel F, Brizard A, Fourcin M, Clemént C, Ingrand P, Daneski L, Gascan H, Wijdenes J, Gombert J, Preud'homme JL, Lecron JC
Clinical and experimental immunology 1997 Jan;107(1):182-8
Clinical and experimental immunology 1997 Jan;107(1):182-8
Analysis of the human interleukin-6/human interleukin-6 receptor binding interface at the amino acid level: proposed mechanism of interaction.
Kalai M, Montero-Julian FA, Grötzinger J, Fontaine V, Vandenbussche P, Deschuyteneer R, Wollmer A, Brailly H, Content J
Blood 1997 Feb 15;89(4):1319-33
Blood 1997 Feb 15;89(4):1319-33
Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop.
Gu ZJ, Costes V, Lu ZY, Zhang XG, Pitard V, Moreau JF, Bataille R, Wijdenes J, Rossi JF, Klein B
Blood 1996 Nov 15;88(10):3972-86
Blood 1996 Nov 15;88(10):3972-86
In vivo role of IL-6 on the viral load and on immunological abnormalities of HIV-infected patients.
Marfaing-Koka A, Aubin JT, Grangeot-Keros L, Portier A, Benattar C, Merrien D, Agut H, Aucouturier P, Autran B, Wijdenes J
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996 Jan 1;11(1):59-68
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996 Jan 1;11(1):59-68
Combination therapy of anti-CD4 and anti-IL6 monoclonal antibodies in a case of severe spondylarthropathy.
Wendling D, Racadot E, Toussirot E, Wijdenes J
British journal of rheumatology 1996 Dec;35(12):1330
British journal of rheumatology 1996 Dec;35(12):1330
Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments.
Lu ZY, Brailly H, Wijdenes J, Bataille R, Rossi JF, Klein B
Blood 1995 Oct 15;86(8):3123-31
Blood 1995 Oct 15;86(8):3123-31
Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells.
Lu ZY, Zhang XG, Rodriguez C, Wijdenes J, Gu ZJ, Morel-Fournier B, Harousseau JL, Bataille R, Rossi JF, Klein B
Blood 1995 May 1;85(9):2521-7
Blood 1995 May 1;85(9):2521-7
Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus.
Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, Morel-Fourrier B, Brouet JC, Alarcon-Segovia D, Galanaud P, Emilie D
The Journal of experimental medicine 1995 Mar 1;181(3):839-44
The Journal of experimental medicine 1995 Mar 1;181(3):839-44
Clinical and immunological follow-up of patients with AIDS-associated Kaposi's sarcoma treated with an anti-IL-6 monoclonal antibody.
Racadot E, Audhuy B, Duvernoy H, Thyss A, Lang JM, Wijdenes J, Hervé P
Cytokines and molecular therapy 1995 Jun;1(2):133-8
Cytokines and molecular therapy 1995 Jun;1(2):133-8
Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma.
Bataille R, Barlogie B, Lu ZY, Rossi JF, Lavabre-Bertrand T, Beck T, Wijdenes J, Brochier J, Klein B
Blood 1995 Jul 15;86(2):685-91
Blood 1995 Jul 15;86(2):685-91
Therapeutic monoclonal antibodies.
Choy EH, Panayi GS, Kingsley GH
British journal of rheumatology 1995 Aug;34(8):707-15
British journal of rheumatology 1995 Aug;34(8):707-15
Different combinations of retinoids and vitamin D3 analogs efficiently promote growth inhibition and differentiation of myelomonocytic leukemia cell lines.
Defacque H, Dornand J, Commes T, Cabane S, Sevilla C, Marti J
The Journal of pharmacology and experimental therapeutics 1994 Oct;271(1):193-9
The Journal of pharmacology and experimental therapeutics 1994 Oct;271(1):193-9
Pharmacokinetics of interleukin-6 during therapy with anti-interleukin-6 monoclonal antibodies: enhanced clearance of interleukin-6 by a combination of three anti-interleukin-6 antibodies.
Montero-Julian FA, Gautherot E, Wijdenes J, Klein B, Brailly H
Journal of interferon research 1994 Oct;14(5):301-2
Journal of interferon research 1994 Oct;14(5):301-2
Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms.
Emilie D, Wijdenes J, Gisselbrecht C, Jarrousse B, Billaud E, Blay JY, Gabarre J, Gaillard JP, Brochier J, Raphael M
Blood 1994 Oct 15;84(8):2472-9
Blood 1994 Oct 15;84(8):2472-9
Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6.
Legouffe E, Liautard J, Gaillard JP, Rossi JF, Wijdenes J, Bataille R, Klein B, Brochier J
Clinical and experimental immunology 1994 Nov;98(2):323-9
Clinical and experimental immunology 1994 Nov;98(2):323-9
Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody.
Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, Hayden K, Jagannath S, Barlogie B
The New England journal of medicine 1994 Mar 3;330(9):602-5
The New England journal of medicine 1994 Mar 3;330(9):602-5
Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma.
Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M, Boiron JM, Bataille R, Klein B
Blood 1994 Jun 15;83(12):3654-63
Blood 1994 Jun 15;83(12):3654-63
Role of IL-6 in promoting growth of human EBV-induced B-cell tumors in severe combined immunodeficient mice.
Durandy A, Emilie D, Peuchmaur M, Forveille M, Clement C, Wijdenes J, Fischer A
Journal of immunology (Baltimore, Md. : 1950) 1994 Jun 1;152(11):5361-7
Journal of immunology (Baltimore, Md. : 1950) 1994 Jun 1;152(11):5361-7
Effects of an anti-interleukin-6 (IL-6) murine monoclonal antibody in a patient with acute monoblastic leukemia.
Bataille R, Zhang XG, Wijdenes J, Schved JF, Klein B
Medical oncology and tumor pharmacotherapy 1993;10(4):185-8
Medical oncology and tumor pharmacotherapy 1993;10(4):185-8
Role of interleukin-6 in paraneoplastic thrombocytosis.
Blay JY, Favrot M, Rossi JF, Wijdenes J
Blood 1993 Oct 1;82(7):2261-2
Blood 1993 Oct 1;82(7):2261-2
Overall interleukin-6 production exceeds 7 mg/day in multiple myeloma complicated by sepsis.
Lu ZY, Brailly H, Rossi JF, Wijdenes J, Bataille R, Klein B
Cytokine 1993 Nov;5(6):578-82
Cytokine 1993 Nov;5(6):578-82
High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo.
Lu ZY, Brochier J, Wijdenes J, Brailly H, Bataille R, Klein B
European journal of immunology 1992 Nov;22(11):2819-24
European journal of immunology 1992 Nov;22(11):2819-24
Interleukin-6 dependence of advanced malignant plasma cell dyscrasias.
Zhang XG, Bataille R, Widjenes J, Klein B
Cancer 1992 Mar 15;69(6):1373-6
Cancer 1992 Mar 15;69(6):1373-6
Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia.
Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Brochier J, Liautard J, Merlin M, Clement C, Morel-Fournier B
Blood 1991 Sep 1;78(5):1198-204
Blood 1991 Sep 1;78(5):1198-204
IL-6 and IL-6 receptor modulation by IFN-gamma and tumor necrosis factor-alpha in human monocytic cell line (THP-1). Priming effect of IFN-gamma.
Sanceau J, Wijdenes J, Revel M, Wietzerbin J
Journal of immunology (Baltimore, Md. : 1950) 1991 Oct 15;147(8):2630-7
Journal of immunology (Baltimore, Md. : 1950) 1991 Oct 15;147(8):2630-7
Human recombinant dimeric IL-6 binds to its receptor as detected by anti-IL-6 monoclonal antibodies.
Wijdenes J, Clement C, Klein B, Morel-Fourrier B, Vita N, Ferrara P, Peters A
Molecular immunology 1991 Nov;28(11):1183-92
Molecular immunology 1991 Nov;28(11):1183-92
IFN-alpha induces autocrine production of IL-6 in myeloma cell lines.
Jourdan M, Zhang XG, Portier M, Boiron JM, Bataille R, Klein B
Journal of immunology (Baltimore, Md. : 1950) 1991 Dec 15;147(12):4402-7
Journal of immunology (Baltimore, Md. : 1950) 1991 Dec 15;147(12):4402-7
No comments: Submit comment
No validations: Submit validation data